|
1
|
Tsugane S and Sasazuki S: Diet and the
risk of gastric cancer: Review of epidemiological evidence. Gastric
Cancer. 10:75–83. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar R, Gururaj AE and Barnes CJ:
p21-activated kinases in cancer. Nat Rev Cancer. 6:459–471. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumar R and Vadlamudi RK: Emerging
functions of p21-activated kinases in human cancer cells. J Cell
Physiol. 193:133–144. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schürmann A, Mooney AF, Sanders LC, Sells
MA, Wang HG, Reed JC and Bokoch GM: p21-activated kinase 1
phosphorylates the death agonist bad and protects cells from
apoptosis. Mol Cell Biol. 20:453–461. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vadlamudi RK, Adam L, Wang RA, Mandal M,
Nguyen D, Sahin A, Chernoff J, Hung MC and Kumar R: Regulatable
expression of p21-activated kinase-1 promotes anchorage-independent
growth and abnormal organization of mitotic spindles in human
epithelial breast cancer cells. J Biol Chem. 275:36238–36244. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Narumiya S, Ishizaki T and Watanabe N: Rho
effectors and reorganization of actin cytoskeleton. FEBS Lett.
410:68–72. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Sullivan GC, Tangney M, Casey G, Ambrose
M, Houston A and Barry OP: Modulation of p21-activated kinase 1
alters the behavior of renal cell carcinoma. Int J Cancer.
121:1930–1940. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ching YP, Leong VY, Lee MF, Xu HT, Jin DY
and Ng IO: P21-activated protein kinase is overexpressed in
hepatocellular carcinoma and enhances cancer metastasis involving
c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
Cancer Res. 67:3601–3608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoon WH, Jung YJ, Kim TD, Li G, Park BJ,
Kim JY, Lee YC, Kim JM, Park JI, Park HD, et al: Gabexate mesilate
inhibits colon cancer growth, invasion, and metastasis byreducing
matrix metalloproteinases and angiogenesis. Clin Cancer Res.
10:4517–4526. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: Trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ellerbroek SM and Stack MS: Membrane
associated matrix metalloproteinases in metastasis. Bioessays.
21:940–949. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liotta LA and Stetler-Stevenson WG: Tumor
invasion and metastasis: An imbalance of positive and negative
regulation. Cancer Res. 51 Suppl 18:5054s–5059s. 1991.PubMed/NCBI
|
|
13
|
Nomura H, Fujimoto N, Seiki M, Mai M and
Okada Y: Enhanced production of matrix metalloproteinases and
activation of matrix metalloproteinase 2 (gelatinase A) in human
gastric carcinomas. Int J Cancer. 69:9–16. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Torii A, Kodera Y, Uesaka K, Hirai T,
Yasui K, Morimoto T, Yamamura Y, Kato T, Hayakawa T, Fujimoto N, et
al: Plasma concentration of matrix metalloproteinase 9 in gastric
cancer. Br J Surg. 84:133–136. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kubben FJ, Sier CF, van Duijn W, Griffioen
G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and
Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic
factor in gastric cancer. Br J Cancer. 94:1035–1040. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sier CFM, Kubben FJGM, Ganesh S, Heerding
MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB and
Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and
MMP-9 are related to the overall survival of patients with gastric
carcinoma. Br J Cancer. 74:413–417. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen W, Xi H, Wei B and Chen L: The
prognostic role of matrix metalloproteinase 2 in gastric cancer: A
systematic review with meta-analysis. J Cancer Res Clin Oncol.
140:1003–1009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gomez DE, Alonso DF, Yoshiji H and
Thorgeirsson UP: Tissue inhibitors of metalloproteinases:
Structure, regulation and biological functions. Eur J Cell Biol.
74:111–122. 1997.PubMed/NCBI
|
|
19
|
Li LH, Luo Q, Zheng MH, Pan C, Wu GY, Lu
YZ, Feng B, Chen XH and Liu BY: P21-activated protein kinase 1 is
overexpressed in gastric cancer and induces cancer metastasis.
Oncol Rep. 27:1435–1442. 2012.PubMed/NCBI
|
|
20
|
Sehgal I and Thompson TC: Novel regulation
of type IV collagenase (matrix metalloproteinase-9 and −2)
activities by transforming growth factor-β1 in human prostate
cancer cell lines. Mol Biol Cell. 10:407–416. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baruch RR, Melinscak H, Lo J, Liu Y, Yeung
O and Hurta RA: Altered matrix metalloproteinase expression
associated with oncogene-mediated cellular transformation and
metastasis formation. Cell Biol Int. 25:411–420. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nair RR and Boyd DD: Expression cloning of
novel regulators of 92 kDa type IV collagenase expression. Biochem
Soc Trans. 33:1135–1136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Muñoz-Nájar UM, Neurath KM, Vumbaca F and
KP; MunozNajar UM Claffey: Hypoxia stimulates breast carcinoma cell
invasion through MT1-MMP and MMP-2 activation. Oncogene.
25:2379–2392. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li YY, McTiernan CF and Feldman AM:
Interplay of matrix metalloproteinases, tissue inhibitors of
metalloproteinases and their regulators in cardiac matrix
remodeling. Cardiovasc Res. 46:214–224. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goldberg GI, Marmer BL, Grant GA, Eisen
AZ, Wilhelm S and He CS: Human 72-kilodalton type IV collagenase
forms a complex with a tissue inhibitor of metalloproteases
designated TIMP-2. Proc Natl Acad Sci USA. 86:8207–8211. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li H, Lindenmeyer F, Grenet C, Opolon P,
Menashi S, Soria C, Yeh P, Perricaudet M and Lu H: AdTIMP-2
inhibits tumor growth, angiogenesis, and metastasis, and prolongs
survival in mice. Hum Gene Ther. 12:515–526. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marino M, Galluzzo P and Ascenzi P:
Estrogen signaling multiple pathways to impact gene transcription.
Curr Genomics. 7:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu B, Jarzynka MJ, Guo P, Imanishi Y,
Schlaepfer DD and Cheng SY: Angiopoietin 2 induces glioma cell
invasion by stimulating matrix metalloprotease 2 expression through
the alphavbeta1 integrin and focal adhesion kinase signaling
pathway. Cancer Res. 66:775–783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hsu HH, Hu WS, Lin YM, Kuo WW, Chen LM,
Chen WK, Hwang JM, Tsai FJ, Liu CJ and Huang CY: JNK suppression is
essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA
and MMP-9 expressions and cell migration in human LoVo colon cancer
cells. J Biomed Sci. 18:61–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheung LW, Leung PC and Wong AS:
Gonadotropin-releasing hormone promotes ovarian cancer cell
invasiveness through c-Jun NH2-terminal kinase-mediated activation
of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res.
66:10902–10910. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chien CS, Shen KH, Huang JS, Ko SC and
Shih YW: Antimetastatic potential of fisetin involves inactivation
of the PI3K/Akt and JNK signaling pathways with downregulation of
MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell
Biochem. 333:169–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
